Pure Biologics S.A. Logo

Pure Biologics S.A.

Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.

PUR | WAR

Overview

Corporate Details

ISIN(s):
PLPRBLG00010 (+1 more)
LEI:
2594002TXS19AUYHIF82
Country:
Poland
Address:
WROCŁAW LEGNICKA 48E, 54-202 WROCŁAW
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pure Biologics S.A. is a biopharmaceutical company focused on the discovery and development of novel biological drugs and non-systemic therapies. The company utilizes its expertise in antibody and aptamer technologies to develop new therapeutic molecules. Its development portfolio primarily targets immuno-oncology and autoimmune diseases. A key element of its strategy is the focus on creating entirely new biological drugs, as opposed to generic or biosimilar alternatives, positioning itself as an innovator in the biotechnology sector.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 11:46
Share Issue/Capital Change
Deklaracja w przedmiocie objęcia akcji nowej emisji - Content (PL)
Polish 1.0 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmieniona treść projektów uchwał NWZ Pure Biologics S.A. zwołanego na dzień 21.…
Polish 204.2 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmieniona treść ogłoszenia o zwołaniu NWZ Pure Biologics S.A. na dzień 21.10.20…
Polish 200.3 KB
2025-10-01 17:28
Pre-Annual General Meeting Information
Zmiana w porządku obrad Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A.…
Polish 1.5 KB
2025-09-30 20:01
Audit Report / Information
Raport niezależnego biegłego rewidenta z badania sprawozdania finansowego Pure …
Polish 287.3 KB
2025-09-30 20:01
Interim Report
Skrócone śródroczne sprawozdanie finansowe Pure Biologics S.A. za okres 1.01.20…
Polish 4.5 MB
2025-09-30 20:01
Interim Report
Jednostkowy raport półroczny Pure Biologics S.A. za okres 1.01.2025-30.06.2025
Polish 2.9 MB
2025-09-24 19:51
Post-Annual General Meeting Information
Treść projektów uchwał NWZ Pure Biologics S.A. zwołanego na dzień 21.10.2025
Polish 201.2 KB
2025-09-24 19:51
Pre-Annual General Meeting Information
Treść ogłoszenia o zwołaniu NWZ Pure Biologics S.A. na dzień 21.10.2025
Polish 199.2 KB
2025-09-24 19:51
Pre-Annual General Meeting Information
Informacja o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. w…
Polish 1.3 KB
2025-09-15 17:57
Share Issue/Capital Change
Podsumowanie emisji akcji serii P1 - Content (PL)
Polish 4.1 KB
2025-09-11 18:03
Report Publication Announcement
Zmiana terminu publikacji raportu półrocznego za I półrocze 2025 r. - Content (…
Polish 863 bytes
2025-09-10 18:43
Legal Proceedings Report
Wycofanie przez Zarząd wniosku o ogłoszenie upadłości Spółki - Content (PL)
Polish 1.9 KB
2025-08-27 17:34
Share Issue/Capital Change
Przydział akcji zwykłych na okaziciela serii P1 - Content (PL)
Polish 954 bytes
2025-07-18 15:21
Share Issue/Capital Change
Zawarcie umowy inwestycyjnej z ACRX Investments Limited - Content (PL)
Polish 3.3 KB

Automate Your Workflow. Get a real-time feed of all Pure Biologics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pure Biologics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480

Talk to a Data Expert

Have a question? We'll get back to you promptly.